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Background: Owing to the high mortality and rapidly growing costs related to lung cancer, it is worth examining the
health benefits of prevention for major types of lung cancer. This study attempts to quantify the quality-adjusted life
expectancy (QALE), loss-of-QALE, and lifetime healthcare expenditures of patients with different pathological types of
lung cancer.
Methods: A national cohort consisting of 66,535 patients with pathologically verified lung cancer was followed for
13 years (1998–2010) to obtain the survival function, which was further extrapolated to lifetime. Between 2011 and
2012, EuroQol 5-dimension questionnaires were used to measure the quality of life (QoL) for 1,314 consecutive,
cross-sectional samples. After multiplying the lifetime survival function by the utility values of QoL, we estimated the
QALE and loss-of-QALE. We also collected the monthly healthcare expenditures, which included National Health
Insurance-reimbursed and out-of-pocket direct medical costs, for 2,456 patients from 2005 to 2012. These values were
multiplied by the corresponding survival probabilities to calculate lifetime healthcare expenditures after adjustments
with medical care inflation rates and annual discount rates.
Results: The QALE for patients with small cell lung cancer, squamous cell carcinoma, and adenocarcinoma were 1.21,
2.37, and 3.03 quality-adjusted life year (QALY), with the corresponding loss-of-QALE of 13.69, 12.22, and 15.03 QALY,
respectively. The lifetime healthcare expenditures were US$ 18,455 ± 1,137, 20,599 ± 1,787, and 36,771 ± 1,998,
respectively.
Conclusions: The lifelong health impact and financial burdens in Taiwan are heavier for adenocarcinoma than for
squamous cell carcinoma. The cost-effectiveness of prevention programs could be directly compared with that of
treatment strategies to improve patient value. And the methodology could be applied to other chronic diseases for
resources planning of healthcare services.
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Over the past two decades, mortality attributed to lung
cancer has increased [1], and it has become the leading
cause of cancer deaths [1,2]. Owing to the development
of new interventions to diagnose and treat lung cancer,
lung cancer care costs are continuously rising [3]. There-
fore, healthcare providers are now facing an increased* Correspondence: jdwang121@gmail.com
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reproduction in any medium, provided the orburden of caring for lung cancer patients. It is thus
worth examining the health benefits of prevention for
major types of lung cancer.
For assessing health benefits, both survival and quality
of life (QoL) should be taken into consideration, and
quality-adjusted life expectancy (QALE) using quality-
adjusted life year (QALY) as the unit may be more suit-
able than estimating survival alone for the purpose of
comparison of various types of healthcare services [4-6].
Previous studies mostly have focused on cross-sectional
analyses of the economic burden of lung cancer [7,8].
However, lifetime medical costs should be estimated to
evaluate the cost-utility of prevention programs. Althoughd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the National Health Insurance (NHI) available in Taiwan,
there are out-of-pocket medical costs that must be esti-
mated to obtain the lifetime healthcare expenditures attrib-
utable to lung cancer. Transportation costs, payments to
caregivers, home adaptation due to illness and human cap-
ital loss were not taken into consideration in this analysis.
Since treatments and prognoses for different patho-
logical subtypes of lung cancer are different, we hypothe-
sized that they may impact mortality, QoL, and medical
costs to different degrees. Based on data from the National
Cancer Registry, NHI reimbursements, and National
Cheng Kung University Hospital (NCKUH), this study is
aimed at quantifying the QALE, loss-of-QALE and life-
time healthcare expenditures that occur in patients with
different subtypes of lung cancer that would be regained
through successful prevention initiatives.
Methods
The Institutional Review Board of NCKUH approved
this study before its initiation (Approval number: ER-
100-079), and every patient interviewed provided written
informed consent. This study abstracted data from the
National Cancer Registry for survival analysis, combined
this with the national life tables to extrapolate the sur-
vival function to lifetime, collected QoL and costs data
from lung cancer patients in NCKUH, and integrated
the survival function with the QoL and costs to estimate
the life expectancy, QALE, loss-of-QALE, and lifetime
healthcare expenditures per case of lung cancer. QALE
was estimated using the following equation [9-11]:
QALE ¼ ∫E QoL t=xð Þ½ S t=xð Þdt
E[QoL(t/x)] denotes the expected value of the QoL
function for condition x at time t, and S(t/x) denotes the
survival function for condition x at time t. The entire de-
sign is summarized in Figure 1.
National Cancer Registry for estimation of the
survival function
All patients with lung cancer during the period from 1998
to 2007 were abstracted from the National Cancer Regis-
try database. The diagnosis of lung cancer and its subtypes
was based on either histology or cytology codes taken
from the International Classification of Diseases [12]. The
survival status for each patient was verified by linking the
patient’s identification information to the National Mor-
tality Registry database. Each patient underwent follow-up
from the day of diagnosis until the end of 2010.
Extrapolating the survival to lifetime
After obtaining the survival function of the lung cancer
cohort, a method proposed by Huang and Wang [13]was used to extrapolate this curve beyond the end of the
follow-up period. This approach assumes that lung can-
cer generates a constant excess hazard (i.e., mortality)
after a certain follow-up period, and its calculation is
carried out in three steps. First, we took the hazard func-
tions from the life tables of the National Vital Statistics
of Taiwan to generate an age- and sex-matched reference
population using the Monte Carlo method and then esti-
mated the survival function. Second, we calculated the
survival ratio between the lung cancer cohort and the ref-
erence population at each time t and performed a logit
transformation of this. Third, the logit transformation of
the ratio was fitted by simple linear regression up to the
end of the follow-up period. The estimated regression line,
together with the survival function of the reference popu-
lation beyond the follow-up limit, was used to extrapolate
the lifetime survival function of the lung cancer cohort,
and thus the life expectancy of the lung cancer cohort
(up to 600 months) after diagnosis could be estimated.
Expected years of life lost in the lung cancer cohort were
defined as the survival difference between the cohort and
the reference population. The method described above
has been demonstrated to be effective using computer
simulations [13], proven mathematically [14], and corrob-
orated by several examples of cancer cohorts [15,16]. The
iSQoL statistical package [17] was used to facilitate the
computation. To validate the extrapolation method de-
scribed above, we used the survival data of patients who
were diagnosed during the first seven years and then ex-
trapolated them to 13 years. Because these patients were
actually followed until the end of 2010, the mean survival
duration within the 13-year follow-up period, using
the Kaplan-Meier method, was considered as the gold
standard. The relative bias was computed to compare the
difference in values between the extrapolation and the
Kaplan-Meier estimation.
Measuring the QoL from a cross-sectional sample
From May 2011 to April 2012, all consecutive patients
with lung cancer from the outpatient oncology, chest
surgery, and chest medicine departments of NCKUH
were invited to participate in this study. To enrich our
sample, we also screened patients admitted to the wards
between November 2011 and January 2012. The inclu-
sion criteria included the realization of a lung cancer
diagnosis in the participants, the absence of malignancy
at another site, and the subjects’ ability to understand
and answer the questionnaire. In some individuals, mea-
surements were performed repeatedly; however, each
measurement took place 3 months apart.
The EuroQol 5-dimension questionnaire (EQ-5D) [18,19],
which is a preference-based generic instrument, was used
to estimate the QoL utility values. The five dimen-
sions assessed by EQ-5D are mobility, self care, usual
Figure 1 Flow diagram of the inclusion of subjects and their relevant information for estimation. EQ-5D: EuroQol 5-dimension questionnaire;
NCKUH: National Cheng Kung University Hospital; QALE: quality-adjusted life expectancy.
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with three levels of severity. Using the scoring function
from the United Kingdom [20], these health state pa-
rameters were transformed into a utility value ranging
from 0 to 1, in which 0 represents death and 1 indi-
cates perfect health.
The duration-to-date for each measurement was de-
fined as the period between the date the lung cancer
diagnosis was made and that of the interview. A kernel-
smoothing method (i.e., the moving average of the
nearby 10%) was used to estimate the mean QoL func-
tion [10,11]. The QoL utility values beyond the follow-
up period were assumed to be the same as the average
of the last 10% of patients near the end of follow-up.Estimating the QALE and loss-of-QALE
The lifetime survival function of the lung cancer cohort
was adjusted using the corresponding mean QoL func-
tion to obtain a quality-adjusted survival curve, in which
the sum of the area under the curve was the QALE of
the lung cancer patients [10]. The loss-of-QALE was cal-
culated by subtracting the area under the quality-
adjusted survival curve of the lung cancer patients from
that of the reference population. Because the EQ-5D
scoring function for Taiwanese residents is still under
development, we tentatively assumed the QoL score of
the reference population to be 1 [10,13]. However, we
also tested the assumption in sensitivity analysis as-
suming the average QoL values of 0.9 and 0.95 for
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[17], which can be downloaded for free, to facilitate
the computation.
Estimating the lifetime healthcare expenditures
The reimbursement database at NCKUH was used to
obtain spending details on medical services for lung can-
cer patients between January 2005 and December 2012.
As these data included not only medical costs paid by
the NHI but also out-of-pocket money, most direct
medical costs attributable to lung cancer could thus be
obtained to calculate the total monthly healthcare ex-
penditures. These were then divided by the effective
sample sizes, namely, the number of lung cancer patients
who survived that month, to obtain the average monthly
healthcare expenditures per case. These values were sub-
sequently multiplied by the corresponding monthly sur-
vival probabilities and summed up to obtain the lifetime
healthcare expenditures per case. All the payments in
different calendar years were adjusted based on the re-
lated consumer price indices [21] and made equivalent
to those in 2012. To discount costs in future years, we
also adjusted the healthcare expenditures, using an an-
nual discount rate of 3%. Because patients might incur
expenses outside the hospital, we compared the costs we
estimated with the costs reimbursed in the national
database by using the same group of patients (2005–
2007). The proportion of reimbursement at NCKUH
was estimated. A total of 1,002 patients ever cared at the
NCKUH were linked with the reimbursement database
of NHI, of which 11 cases could not be successfully con-
nected. There were 4 cases (2 cases of small cell lung
cancer (SCLC) and 2 cases of non-small cell lung cancer
(NSCLC)) with the difference on the date of diagnosis
larger than 1,000 days and were not included for the
above calculation.
Results
The lung cancer cohort from the National Cancer Registry
database used to obtain the survival function consisted of
66,535 patients. A total of 964 lung cancer patients visited
NCKUH between 2011 and 2012, and 676 patients met
the criteria for inclusion. Individuals who declined to
answer the questionnaire were excluded, leaving 635
patients. However, 17 of these had incomplete data,
and thus the cross-sectional sample for measuring the
QoL consisted of a total of 618 patients, and 1,314 QoL
measurements were performed. The average number of
measurements per person was 2.1. In addition, the reim-
bursement database in NCKUH included details of health-
care expenditures for 2,456 lung cancer patients from
2005 to 2012. Table 1 summarizes the descriptive statistics
of the national cohort for survival function and the
NCKUH cohort for healthcare expenditures. By using thesame method, patients with NSCLC in the NCKUH co-
hort were found to have longer life expectancy and greater
NHI-reimbursed lifetime healthcare expenditures than
those in the national cohort, which can be partially ex-
plained by the advancement of NSCLC treatment in the
past five years and different frequency distributions of
pathological subtypes in the two groups.
The QALE and loss-of-QALE
After multiplying the survival probability with the mean
QoL at each time t (duration-to-date), we obtained the
quality-adjusted survival curve, as shown in Figure 2.
The sum of the shaded area under the curve represents
the QALE. Assuming that the QoL of age- and sex-
matched referents was 1, the difference between the
quality-adjusted survival curve of patients and that of
the referents was the loss-of-QALE (Figure 3). The
QALE for patients with SCLC and NSCLC was 1.21 and
2.65 QALY, respectively, while the loss-of-QALE for the
two groups was 13.69 and 14.08 QALY, respectively.
Compared with NSCLC patients with squamous cell car-
cinoma (SqCC), those with adenocarcinoma had a longer
QALE (3.03 vs. 2.37 QALY, p < 0.001, Table 2). Moreover,
we found that the loss-of-QALE of adenocarcinoma pa-
tients was significantly greater than that of SqCC patients
(15.03 vs. 12.22 QALY, p < 0.001), probably because of
the younger mean age at diagnosis (65.60 vs. 69.35 years,
p < 0.001).
The lifetime healthcare expenditures
Using the kernel-smoothing method, the average health-
care expenditures per case of patients with SCLC and
NSCLC are depicted in Figure 4. It shows that the
medical costs reimbursed by the NHI decreased grad-
ually after the diagnosis; however, the out-of-pocket
medical costs in the terminal phase of NSCLC in-
creased. Compared NHI-reimbursed costs of the 987
patients in our hospital with those in the national
database, we found that healthcare costs of the NCKUH
for SCLC and NSCLC patients accounted for 74.3%
and 84.1%, respectively, of the total costs reimbursed
by the NHI.
Table 2 also shows the lifetime healthcare expenditures
per case for patients with different NSCLC subtypes, ad-
justed for medical care inflation rates up to the year 2012
and for annual discount rates in future years. Compared
with SqCC patients, adenocarcinoma patients had greater
lifetime healthcare expenditures per case (US$ 36,771 ±
1,998 versus US$ 20,599 ± 1,787), especially in regard to
out-of-pocket medical costs (US$ 18,620 ± 1,857 versus
US$ 6,350 ± 741). Moreover, we found that both the
annual healthcare expenditures and cost-per-QALY at-
tributable to adenocarcinoma were higher than those
for SqCC.
Table 1 Comparison between the national cohort and the cohort from National Cheng Kung University
Hospital (NCKUH)
The national cohort The NCKUH cohort P value*
Calendar years of collection 1998-2007 2005-2012
Total number of patients 66,535 2,456
Age at diagnosis, mean (SD) years 67.22 (12.10) 65.57 (12.57)
Sex, no. of males (%) 45,098 (67.78) 1,457 (59.32)
SCLC, no. of patients (%) 6,748 (10.14) 337 (13.72)
Life expectancy, mean (SE) years 1.43 (0.02) 1.44 (0.10) 0.906
Lifetime healthcare expenditures per case,
NHI-reimbursed medical costs, mean (SE) $ 12,597 (703) 15,454 (1,520) 0.105
Out-of-pocket medical costs, mean (SE) $ – 4,797 (550)
NSCLC, no. of patients (%) 59,787 (89.86) 2,119 (86.28)
Life expectancy, mean (SE) years 3.05 (0.01) 3.19 (0.05) 0.011
Lifetime healthcare expenditures per case,
NHI-reimbursed medical costs, mean (SE) $ 18,660 (894) 21,965 (1,364) 0.049
Out-of-pocket medical costs, mean (SE) $ – 15,807 (872)
–: not applicable; SD: standard deviation; SE: standard error; NHI: National Health Insurance; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer.
*Comparison using Z-statistic.
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There were 4,425 patients with SCLC and 38,509 patients
with NSCLC diagnosed during the first seven years, be-
tween 1998 and 2004, of which the survival curves were
extrapolated to 2010 and compared with the Kaplan-Figure 2 The QALE (quality-adjusted life expectancy) of
patients with small cell lung cancer (SCLC, upper panel) and
non-small cell lung cancer (NSCLC, lower panel). The survival
curves (dashed lines), mean utility functions (dotted lines), and
quality-adjusted survival curves (solid lines) of patients with lung
cancer are depicted, and the shaded area represents the QALE.Meier estimates based on the 13-year follow-up (Table 3).
The relative biases of the extrapolation ranged between +
7.71% (p = 0.122) and + 1.29% (p = 0.551).
Discussion
Although the incidence of adenocarcinoma (50.60%) was
about twice that of SqCC (25.24%) during the period
1998–2007, according to the data from the National
Cancer Registry, the former has not attracted as much
attention as the latter, which is associated with cigaretteFigure 3 The QAS (quality-adjusted survival) curves of patients
with squamous cell carcinoma (SqCC), adenocarcinoma and the
corresponding referents. The difference between the QAS curve of
patients and that of the corresponding referents was the loss-of-QALE
(quality-adjusted life expectancy). SqCC patients: solid line; age- and
sex-matched referents of SqCC: dotted line; adenocarcinoma patients:
long-dashed line; age- and sex-matched referents of adenocarcinoma:
short-dashed line.
Table 2 The QALE (quality-adjusted life expectancy), loss-of-QALE, healthcare expenditures (in US dollars) of lung
cancer patients
NSCLC (n = 59,787)
SqCC (n = 16,796) Adenocarcinoma (n = 33,669) Other NSCLCs* (n = 9,322)
Age at diagnosis, mean (SD) years 69.35 (10.63) 65.60 (12.84) 68.12 (12.11)
Sex, no. of males (%) 14,423 (85.87) 18,075 (53.68) 6,625 (71.07)
Life expectancy, mean (SE) years 2.73 (0.02) 3.46 (0.02) 1.99 (0.02)
Expected years of life lost, mean (SE) years 11.84 (0.03) 14.61 (0.03) 13.91 (0.03)
QALE, mean (SE) QALY 2.37 (0.05) 3.03 (0.03) 1.74 (0.07)
Loss-of-QALE, mean (SE) QALY
Assumed mean utility of referents = 1 12.22 (0.05) 15.03 (0.04) 14.17 (0.08)
Assumed mean utility of referents = 0.95 11.45 (0.05) 14.16 (0.03) 13.35 (0.08)
Assumed mean utility of referents = 0.9 10.75 (0.05) 13.25 (0.04) 12.58 (0.08)
Lifetime healthcare expenditures per case,
NHI-reimbursed medical costs, mean (SE) $ 14,249 (1,435) 18,150 (1,469) 12,918 (1,156)
Out-of-pocket medical costs, mean (SE) $ 6,350 (741) 18,620 (1,857) 7,439 (842)
Healthcare expenditures/life-year per case, mean (SE) $ 9,281 (803) 13,636 (754) 12,546 (1,050)
Healthcare expenditures/QALY per case, mean (SE) $ 10,841 (980) 15,642 (885) 14,475 (1,400)
SD: standard deviation; SE: standard error; NSCLC: non-small cell lung cancer; QALY: quality-adjusted life year; SqCC: squamous cell carcinoma.
*Large cell carcinoma, adenosquamous cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, carcinoid tumor and unspecified carcinoma.
Figure 4 The healthcare expenditures per case of patients with
small cell lung cancer (SCLC, upper panel) and non-small cell
lung cancer (NSCLC, lower panel). The medical costs reimbursed
by the National Health Insurance (NHI) are depicted in solid lines
and out-of-pocket medical costs are depicted in dotted lines.
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preventative efforts for the last few decades. There is a
general impression that long-term survival is similarly
poor with all types of NSCLC, a view that is corrobo-
rated by the results of this study, which found a life ex-
pectancy of 2.73 versus 3.46 years for patients with
SqCC and adenocarcinoma, respectively (Table 2). How-
ever, after adjustment for the age at onset, the latter
group suffered from 2.77 (= 14.61-11.84) additional years
of life lost in comparison with the former, which was
equivalent to 2.81 (= 15.03-12.22) QALY more loss-of-
QALE (Table 2). Moreover, the average healthcare
expenditures per life-year for patients with adenocarcin-
oma were 46.9% (= (13,636-9,281)/9,281) higher than
that of SqCC patients, while the average lifetime health-
care expenditures were 78.5% (= (36,771-20,599)/20,599)
higher. As this study is limited to cases with pathological
evidence that were followed for 13 years, sex- and age-
matched for estimating the life expectancy, and adjusted
for the QoL and costs of an actual cohort, the estimation
is not confounded by the factors listed above. In
addition, the validation of our extrapolation method has
shown that the relative biases were all less than 7.71%
after 6 years of extrapolation (Table 3). We thus tenta-
tively conclude that, in Taiwan, the lifelong health im-
pact and financial burdens of adenocarcinoma are heavier
than those of SqCC and deserve effort with regard to
prevention.
Several risk factors for adenocarcinoma have been iden-
tified. In addition to cigarette smoking, indoor exposure
to radon gas is perhaps one of the most important [23,24]




estimate, mean (SE) months
Estimate using the extrapolation based on
the first 7 years of follow-up, mean (SE) months
Relative bias,% P value*
SCLC 4,425 14.75 (0.45) 15.42 (0.38) +4.54 0.424
NSCLC 38,509 25.27 (0.24) 25.89 (0.16) +2.45 0.165
SqCC 11,507 25.51 (0.43) 26.21 (0.31) +2.74 0.528
Adenocarcinoma 20,926 27.05 (0.30) 27.40 (0.23) +1.29 0.551
Other NSCLCs 6,076 18.68 (0.44) 20.12 (0.37) +7.71 0.122
SE: standard error; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; SqCC: squamous cell carcinoma.
*Comparison using Z-statistic.
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among non-smoking women also appears to be associated
with cooking fume exposure and lack of ventilation con-
trol [25-27]. By carefully studying and controlling these
risk factors, more life-years and QALY lost, as well as
healthcare expenses, might be saved.
Unlike previous studies that have used internationally-
selected life tables together with expert determination of
QoL values to calculate the disease burden of lung can-
cer with the disability-adjusted life year (DALY) unit
[28,29], our study used the national life tables of Taiwan
and a cross-sectional sample of patients for measure-
ment of QoL to estimate the QALE and loss-of-QALE
using QALY. While the DALY method makes inter-
national comparisons more feasible, the QALY unit
calculated by our method can directly compare different
prevention, diagnosis, and treatment strategies, and
would probably be more feasible for national health
policy decisions. However, the utility values of NSCLC
patients reported by our cross-sectional sample were
higher than those reported in other studies [30,31], and
this may be due to several reasons. First, all patients
must be healthy enough to accept our interview invita-
tions and most (85.4%, 528 of 618 patients) of our sub-
jects were recruited from outpatient departments. They
were less likely to have any severe adverse effect and
would have higher utility scores [30]. In addition, 59.1%
(365 of 618 patients) of our subjects did not have any
evidence of metastasis, which would make the average
scores of our patients be higher than those with 63.2%
of metastasis [31]. Second, because insight into the diag-
nosis of lung cancer was one of the inclusion criteria
required by the Institutional Review Board, the utility
values of our patients were usually higher [32]. Third,
while extrapolating the QoL function to lifetime, it was
assumed that patients remained at the same level of
QoL near the end of the follow-up period. Such an as-
sumption could result in an overestimated or higher
QoL score because actual utility value usually declines
with age [33]. Hence, the QALE would be overestimated
while the loss-of-QALE would be underestimated.
The lifetime healthcare expenditures for adenocarcin-
oma, even if we look at the expenditures per life-year,were higher than those for SqCC. This can be at least
partially explained by the fact that the patients with
adenocarcinoma were 3.75 years younger than those
with SqCC and usually received more aggressive forms
of treatments, which included newly developed chemo-
therapeutic agents (such as premetrexed, gefitinib, erloti-
nib, and so on). Most costs of these treatments were
out-of-pocket medical costs, which were administered in
the later and/or terminal phase of the disease, as also
shown on Figure 4. When estimating the lifetime health-
care expenditures, we adjusted the dollar values through-
out the 2005–2012 period to that of 2012. In addition, the
current estimates were adjusted for an annual discount
rate of 3% in future years. Comparisons with studies from
other countries [34,35] reveal that the lifetime healthcare
expenditures reimbursed by the NHI in Taiwan seem rela-
tively small. This could be explained by the different prices
of medical care in different countries.
Several limitations must be acknowledged in our study.
First, the QoL score of the reference population was
assumed to be 1, whereas the reference population might
include people with other illnesses and, as a result, the
loss-of-QALE due to lung cancer might be overestimated.
However, we have tested the assumption in sensitivity ana-
lysis and assessed its impact on the results (Table 2). In
addition, since both reference groups for the two different
subtypes of lung cancer were treated in the same way, the
difference between them would not be confounded. Sec-
ond, although the estimated lifetime healthcare expendi-
tures represented not only the medical costs paid by the
NHI but also the out-of-pocket money, there were still
other expenses paid by the patients and/or their families,
including transportation costs, payments made to care-
givers, and human capital loss (i.e. the foregone earnings),
which we did not take into consideration. Nevertheless,
our estimations could be considered as a lower bound and
may be useful for future lung cancer prevention programs
planned by the related health authorities. Third, as the
data abstracted from the National Cancer Registry for
survival analysis did not have detailed information of
tumor stages, we could not do further subgroup ana-
lysis regarding the staging issue. Because about three-
fourth of NSCLC and all SCLC patients are inoperable,
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Lastly, the estimation of QALE would have been more
accurate if we had obtained the QoL follow-up for every
patient in the lung cancer cohort. Future longitudinal
studies are indicated to corroborate our results based on
cross-sectional samples.
Conclusions
In conclusion, this study successfully estimated the
QALE, loss-of-QALE, and the lifetime healthcare expen-
ditures of patients with different lung cancer subtypes.
We found that adenocarcinoma produces higher loss-of-
QALE and lifetime healthcare expenditures than is seen
with SqCC. Future research could focus on the cost-
effectiveness of different prevention programs targeted
at different types of lung cancer to obtain the cost-per-
life year and/or cost-per-QALY, and provide policy rec-
ommendations. In addition, the methodology could be
applied to other cancers or chronic diseases for resources
planning of healthcare services.
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